We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biosimilars Council Says Patent Abuse Chills Competition, Costs Billions
Biosimilars Council Says Patent Abuse Chills Competition, Costs Billions
Biosimilar companies are hamstrung by patent schemes, misguided legislation, rebate traps and other hurdles to market entry that have cost the U.S. healthcare system $7.6 billion since 2015, the Biosimilar Council claims in a new analysis.